MET expression appears to have a significant prognostic value for HNSCC patients treated with radiotherapy within the TCGA cohort when analyzing disease-specific (p = 0.033, HR = 2.431) and progression-free survival (p = 0.043, HR = 1.574). This evidence concerns the gene MET and head and neck squamous cell carcinoma.